Moderna (MRNA) is under pressure after investors digested a cut to the upper end of its 2025 revenue forecast, a move tied to delayed vaccine deliveries. The company’s message is that demand and longer-term plans may be intact, but the near-term revenue profile is softer because shipments expected in the second half of 2025 are now expected to occur in the first quarter of 2026. (cnbc.com)

Moderna updated its 2025 revenue range to $1.5 billion to $2.2 billion, down from the prior $1.5 billion to $2.5 billion at the high end. The company attributed the roughly $300 million reduction in the ceiling to a timing shift in COVID vaccine shipments to the U.K., pushing revenue recognition out of 2025 and into early 2026. (cnbc.com)

With Moderna still heavily reliant on respiratory vaccine cash flows while it works to scale newer products, any reduction in the near-term revenue ceiling can amplify concerns about the pace of the transition away from pandemic-era COVID sales. The selloff reflects skepticism about visibility and execution on deliveries and commercialization timing, even when the driver is framed as a shipment-date shift rather than a collapse in underlying demand. (biopharmadive.com)

Key near-term items include confirmation that the delayed U.K. shipments occur as expected in early 2026, updates to procurement cadence in international markets, and additional detail on how cost actions align with Moderna’s multi-year plan to stabilize cash burn. Any incremental updates on combination respiratory vaccines and late-stage pipeline timelines could also influence whether investors treat the move as a one-off timing issue or part of a broader revenue reset. (irp.cdn-website.com)